Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BKXLI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HuAb3v2.6-AAA
|
|||||
| Synonyms |
huAb3v2.6 AAA; huAb3v2.6AAA
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
huAb3v2.6
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
huAb3v2.6-AAA linker
|
|||||
| Combination Type |
AbbVie's AAA
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Effective Concentration (EC50) |
1.24
|
nM
|
NCI-H1650 cells
|
Lung adenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 47% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
|
||||
| In Vivo Model | H146 CDX model | ||||
| In Vitro Model | Small cell carcinoma | NCI-H146 cells | CVCL_1473 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 50% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q14Dx3/IP).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 60% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q14Dx3/IP).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 63% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q14Dx3/IP).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 92% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 99% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 99% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.24 nM | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||